Alivus Life Sciences
- P/E
- 30.95
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 23.80%
- Debt to Equity
- 0.02
- EPS (TTM)
- ₹49.14
- Book Value
- ₹295.78
- Market Cap
- —
- P/E (TTM)
- 30.95
- P/B
- 5.14
- ROE
- 17.90%
- Dividend Yield
- 0.34%
- EBITDA
- ₹858 Cr
- 52W High
- ₹1,529.00
- 52W Low
- ₹819.00
- Day Range
- ₹1,450.10 – ₹1,529.00
- Volume
- 4,87,350
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Alivus Life Sciences (this company) | ₹1,520.70 | 30.95 | ₹18,070 Cr | 5.14 | 0.34% | 17.90% | 23.80% | ₹2,590 Cr | ₹603 Cr |
| Median 8 companies | ₹1,647.05 | 37.20 | ₹1,25,337 Cr | 4.96 | 0.46% | 17.20% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 73
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 63
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 30
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 83
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 74
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.4%
Weaknesses
2- The company has delivered a poor sales growth of 6.24% over past five years.
- Company has high debtors of 153 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 4 | 2 | 13 |
| Oscillators | Bearish | 4 | 2 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 73.44
- Bearish
- MACD (12,26,9)
- 28.83
- Bullish
- SMA (50)
- 1,369.08
- Bullish
- SMA (200)
- 1,132.03
- Bullish
As of
Analyst Rating
4 of 4 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +6.25% |
|---|---|
| 3Y | +5.70% |
| 1Y | +6.91% |
| TTM | +7.87% |
Net profit
| 5Y | +9.89% |
|---|---|
| 3Y | +6.49% |
| 1Y | +16.05% |
| TTM | +21.57% |
Operating cash flow
| 5Y | +7.81% |
|---|---|
| 3Y | +22.68% |
| 1Y | +44.13% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −0.14 pp |
|---|---|
| 3Y | +1.52 pp |
| 1Y | +2.61 pp |
| TTM | +3.42 pp |
Revenue by year
| Mar 2018 | ₹0.00 Cr |
|---|---|
| Mar 2019 | ₹886 Cr |
| Mar 2020 | ₹1,537 Cr |
| Mar 2021 | ₹1,885 Cr |
| Mar 2022 | ₹2,123 Cr |
| Mar 2023 | ₹2,161 Cr |
| Mar 2024 | ₹2,283 Cr |
| Mar 2025 | ₹2,387 Cr |
| Mar 2026 | ₹2,552 Cr |
Net profit by year
| Mar 2018 | ₹0.00 Cr |
|---|---|
| Mar 2019 | ₹196 Cr |
| Mar 2020 | ₹313 Cr |
| Mar 2021 | ₹352 Cr |
| Mar 2022 | ₹419 Cr |
| Mar 2023 | ₹467 Cr |
| Mar 2024 | ₹471 Cr |
| Mar 2025 | ₹486 Cr |
| Mar 2026 | ₹564 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Alivus Life Sciences Ltd trades at ₹1,520.7 as of 2026-11-04 with a market cap of ₹18,069.5 crore and a P/E (TTM) of 30.95x. The company is virtually debt-free with a debt-to-equity ratio of 0.02 and has delivered a TTM profit growth of 25%, though its five-year compounded sales growth stands at just 6%.
- The company is almost debt-free with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and low interest-rate risk.
- TTM profit growth of 25% marks a sharp acceleration compared to the 3-year compounded profit growth of 6% and the 5-year rate of 9%, suggesting improving profitability.
- ROCE of 21.78% indicates efficient capital deployment, well above the cost of capital for most Indian companies.
- The stock has delivered a 1-year CAGR of 42% and a 3-year CAGR of 28%, reflecting strong market confidence and momentum.
- ROE of 16.94% (current) with a 5-year average of 21% demonstrates consistent ability to generate returns on shareholders' equity.
- The company maintains a healthy dividend payout of 27.4%, offering a dividend yield of 0.34% while still retaining capital for growth.
- Trading near its 52-week high of ₹1,529 (current price ₹1,520.7) suggests sustained bullish sentiment and price discovery at elevated levels.
- P/B ratio of 5.14x, while optically high, is supported by a combination of low leverage and double-digit ROE, indicating the market is pricing in quality attributes.
- Five-year compounded sales growth of only 6% indicates sluggish top-line expansion for a healthcare company commanding a P/E of 30.95x.
- High debtor days of 153 days signals significant working capital strain and potential collection risk, tying up cash in receivables.
- At a P/E (TTM) of 30.95x, the stock is richly valued relative to its modest 5-year profit CAGR of 9%, implying the market is pricing in a sustained acceleration that may not materialise.
- Three-year compounded sales growth of 6% mirrors the 5-year figure, suggesting the revenue slowdown is structural rather than cyclical.
- ROE has declined from a 5-year average of 21% to 18% last year and 16.94% currently, indicating a downward trend in return generation.
- TTM sales growth of 8% only modestly outpaces the 5-year compounded rate of 6%, suggesting that the profit acceleration to 25% may be margin-driven and potentially unsustainable.
- The stock is up 85.7% from its 52-week low of ₹819 to ₹1,520.7, raising the risk of mean reversion or profit-booking at current levels.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Alivus Life Sciences shows no major positive or negative catalysts in recent weeks. The company is actively engaging institutional investors through multiple scheduled meetings in November 2026, which signals ongoing investor relations effort. A minor ₹25.61 lakh CGST order poses negligible financial risk. With limited newsflow, the near-term outlook hinges on whether the broadening investor outreach translates into meaningful institutional interest.
- Expanding investor meeting schedule Nov 3
Alivus Life Sciences added Avarta Capital, BOI Mutual Fund, and Bandhan Mutual Fund to its November 2026 investor meeting schedule, with sessions on November 6 and 12 in Mumbai alongside previously announced meetings with Edelweiss and Axis Max Life.
- Minor CGST tax order received Oct 9
Alivus received a CGST order for FY21-22 involving ₹25.61 lakh in tax and penalty. The company states no material impact on operations and is evaluating an appeal.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | 682 |
| Expenses | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 | 417 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | 265 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% | 39% |
| Other Income | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | −12 | 23 | 22 | 20 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 | 22 |
| PBT | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | 262 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% | 25% |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | 197 |
| EPS (₹) | 11.05 | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 | — |
Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Expenses | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,754 | 1,754 |
| Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 34.57 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| PBT | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% | — |
| Net Profit | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS (₹) | −3.91 | 18.14 | 29.04 | 32.61 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Div. Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | −1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Investing | 0 | −9 | −51 | −69 | −122 | −147 | −116 | −616 | −570 |
| Financing | 0 | 1 | −137 | −214 | −79 | −388 | −279 | −6 | −64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | −228 | 18 | −230 | −69 |
| Free Cash Flow | 0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/EBITDA | 4,800 | 14 | 61 | 84 | 119 | 71 | 85 | 81 | 93 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | — | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | — | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | — | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | — | −186 | −37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | — | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alivus Life Sciences insights
65 extracted metrics across FY18–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Jan 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 16 Sep 2025
- 19 Jun 2024
- 3 Oct 2023
- 22 Sep 2023
- 19 Jul 2023
- General announcements 3 Nov 2026
- General announcements 30 Oct 2026
- General announcements 29 Oct 2026
Frequently Asked Questions about Alivus Life Sciences
What does Alivus Life Sciences Ltd do?
Where is Alivus Life Sciences Ltd (ALIVUS) listed?
Which sector does Alivus Life Sciences Ltd belong to?
What is the PE ratio of Alivus Life Sciences Ltd?
What is the 52-week high and low of Alivus Life Sciences Ltd?
Does Alivus Life Sciences Ltd pay dividends?
What is the Return on Equity (ROE) of Alivus Life Sciences Ltd?
Company Information
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALIVUS.md for Alivus Life Sciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.